KR20240152889A - 화합물의 다형체 형태 및 다형체 형태의 제조 방법 - Google Patents
화합물의 다형체 형태 및 다형체 형태의 제조 방법 Download PDFInfo
- Publication number
- KR20240152889A KR20240152889A KR1020247031018A KR20247031018A KR20240152889A KR 20240152889 A KR20240152889 A KR 20240152889A KR 1020247031018 A KR1020247031018 A KR 1020247031018A KR 20247031018 A KR20247031018 A KR 20247031018A KR 20240152889 A KR20240152889 A KR 20240152889A
- Authority
- KR
- South Korea
- Prior art keywords
- crystalline form
- compound
- degrees
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311869P | 2022-02-18 | 2022-02-18 | |
| US63/311,869 | 2022-02-18 | ||
| PCT/US2023/012898 WO2023158607A1 (en) | 2022-02-18 | 2023-02-13 | Polymorphic forms and methods of producing polymorphic forms of a compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240152889A true KR20240152889A (ko) | 2024-10-22 |
Family
ID=87578977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247031018A Pending KR20240152889A (ko) | 2022-02-18 | 2023-02-13 | 화합물의 다형체 형태 및 다형체 형태의 제조 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250034183A1 (https=) |
| EP (1) | EP4479409A4 (https=) |
| JP (1) | JP2025508746A (https=) |
| KR (1) | KR20240152889A (https=) |
| CN (1) | CN119053613A (https=) |
| AU (1) | AU2023221889A1 (https=) |
| CA (1) | CA3252569A1 (https=) |
| MX (1) | MX2024010008A (https=) |
| WO (1) | WO2023158607A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1882327A (zh) * | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| EP1891080A2 (en) * | 2005-05-26 | 2008-02-27 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| WO2006128056A2 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| WO2020117962A1 (en) * | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
-
2023
- 2023-02-13 JP JP2024548633A patent/JP2025508746A/ja active Pending
- 2023-02-13 EP EP23756786.2A patent/EP4479409A4/en active Pending
- 2023-02-13 KR KR1020247031018A patent/KR20240152889A/ko active Pending
- 2023-02-13 MX MX2024010008A patent/MX2024010008A/es unknown
- 2023-02-13 CN CN202380034735.3A patent/CN119053613A/zh active Pending
- 2023-02-13 WO PCT/US2023/012898 patent/WO2023158607A1/en not_active Ceased
- 2023-02-13 US US18/836,713 patent/US20250034183A1/en active Pending
- 2023-02-13 AU AU2023221889A patent/AU2023221889A1/en active Pending
- 2023-02-13 CA CA3252569A patent/CA3252569A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025508746A (ja) | 2025-04-10 |
| EP4479409A1 (en) | 2024-12-25 |
| AU2023221889A1 (en) | 2024-08-15 |
| EP4479409A4 (en) | 2025-10-22 |
| US20250034183A1 (en) | 2025-01-30 |
| CA3252569A1 (en) | 2023-08-24 |
| MX2024010008A (es) | 2024-08-22 |
| WO2023158607A1 (en) | 2023-08-24 |
| CN119053613A (zh) | 2024-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3743406B1 (en) | Tmem16a modulators | |
| US20260028309A1 (en) | Polymorphic forms of rad1901-2hcl | |
| US10570099B2 (en) | Salts of an epidermal growth factor receptor kinase inhibitor | |
| CN105873586B (zh) | 一种包含缬沙坦和ahu377的三钠盐超分子复合物的晶型及其制备方法 | |
| CN104302178B (zh) | 表皮生长因子受体激酶抑制剂的固体形式 | |
| KR20240152889A (ko) | 화합물의 다형체 형태 및 다형체 형태의 제조 방법 | |
| US10150770B2 (en) | Crystal form of bisulfate of JAK inhibitor and preparation method therefor | |
| EP3846809A1 (en) | 2,6-diamino pyridine compounds | |
| US20180305397A1 (en) | Preparation and Uses of Obeticholic Acid | |
| CN113423684A (zh) | 新型拟甲状腺素药 | |
| WO2020156459A1 (zh) | 吡咯并嘧啶衍生物及其用途 | |
| CN102070618B (zh) | 一种化合物及其晶体 | |
| TW201335161A (zh) | 二氫吡咯并［１，２－ｃ］咪唑基皮質醛酮素合成酶或芳族酶抑制劑之新穎型式及鹽 | |
| TW201609717A (zh) | Ｐｌｋ－４抑制劑之鹽和結晶形式 | |
| CN113549000A (zh) | 用于预防或治疗脂质代谢相关疾病的化合物 | |
| US10308641B2 (en) | Crystal form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxole-5-yl)cyclopropane formamido)-3-methylpyridine-2-yl)benzoic acid and preparation method thereof | |
| US20240262785A1 (en) | Solid Forms, Salts and Polymorphs of Anti-fibrotic Compounds | |
| KR20210123321A (ko) | 류코트리엔 합성 억제제 | |
| WO2026052060A1 (zh) | 一类苯甲酰基甘氨酸衍生物及其制备方法和应用 | |
| KR20230121762A (ko) | (5s)-사이클로프로필-5-[3-[(3s)-4-(3,5-디플루오로페닐)-3-메틸-피페라진-1-일]-3-옥소-프로필]이미다졸리딘-2,4-디온의 고체 형태 | |
| HK40042091A (en) | Tmem16a modulators | |
| HK40042091B (en) | Tmem16a modulators | |
| WO2012136121A1 (zh) | 氨基苯丙醇类化合物及其用于制备免疫抑制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |